ACTHAR Therapy for Central Nervous System Sarcoidosis
Primary Purpose
Sarcoidosis
Status
Withdrawn
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Repository Corticotropin Injection
Sponsored by
About this trial
This is an interventional treatment trial for Sarcoidosis
Eligibility Criteria
Inclusion Criteria:
- Patient with sarcoidosis as defined by ATS/ERS/WASOG (American Thoracic Society/European Thoracic Society/World Association for Sarcoidosis and Other Granulomatous Disorders)
- Stable baseline immunosuppressive medications
Moderate to severe disease as defined by at least one of the following criteria:
- Cranial nerve palsy
- Neurologic deficits related to intraparenchymal brain, spinal cord and/or cauda equina involvement
- Dural or leptomeningeal involvement of brain and/or spinal cord
- Hydrocephalus
- Seizures
Exclusion Criteria:
- Diagnosis of any underlying neurologic disorder that would potentially confound interpretation of the study results
- Significant change in corticosteroid dose within the past 4 weeks, or other immunosuppressive medication within the past 6 months
- Evidence of current serious infection, or a history of chronic or recurring infections.
- Contraindication to high-dose corticosteroids (e.g. uncontrolled blood sugar).
- Allergies to pig-derived proteins
- Have a history of any opportunistic infection within 6 months prior to screening
- History of malignancy.
Sites / Locations
- Cleveland Clinic Main Campus
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Experimental: H.P. Achtar Gel 80 U
Arm Description
H.P. Acthar Gel (repository corticotropin) Injection, 80 U daily for 10 days, then 80 U twice weekly for up to a total of 48 weeks on therapy.
Outcomes
Primary Outcome Measures
Proportion of patients with clinically significant improvement - successful glucocorticoid tapering.
Secondary Outcome Measures
Proportion of patients with clinically significant improvement - no need for escalation of other therapy.
Full Information
NCT ID
NCT02920710
First Posted
September 29, 2016
Last Updated
November 19, 2020
Sponsor
The Cleveland Clinic
Collaborators
Mallinckrodt
1. Study Identification
Unique Protocol Identification Number
NCT02920710
Brief Title
ACTHAR Therapy for Central Nervous System Sarcoidosis
Official Title
ACTHAR Therapy for Central Nervous System Sarcoidosis
Study Type
Interventional
2. Study Status
Record Verification Date
November 2020
Overall Recruitment Status
Withdrawn
Why Stopped
Difficulty with recruitment
Study Start Date
February 1, 2019 (Actual)
Primary Completion Date
November 2, 2020 (Actual)
Study Completion Date
November 2, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
The Cleveland Clinic
Collaborators
Mallinckrodt
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
There is a need for a more reliable, expeditious therapy that can be used as an alternative to glucocorticoids in severe Central Nervous System (CNS) sarcoidosis. This study aims to provide evidence for effectiveness of ACTHAR gel in CNS sarcoidosis, and provide information about its safety and tolerability
Detailed Description
Central nervous system (CNS) involvement is one of the most severe manifestations of sarcoidosis. Sarcoidosis affecting the leptomeninges, spinal cord, or brain parenchyma portends a difficult course and frequently results in severe disability or death (1). Treatment of moderate and severe CNS sarcoidosis typically involves a combination of corticosteroids and cytotoxic agents such as methotrexate (2). Unfortunately, most response rates are reportedly only in the 29-38% range for corticosteroids alone, and the effects of cytotoxic agents in sarcoidosis require up to 6 months to occur. A typical scenario is that patients are treated for prolonged periods with high dose glucocorticoids with suboptimal effectiveness despite development of substantial toxicities. Some series report that cyclophosphamide or infliximab may be beneficial (3), but these approaches are limited by potentially severe toxicities, loss of effectiveness, or payor constraints.
. ACTHAR is a 39-amino acid peptide natural form of adrenocorticotropin hormone (ACTH) that was initially approved in 1952 by the FDA. It has since been approved for 19 indications including respiratory sarcoidosis, multiple sclerosis, and infantile spasms.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sarcoidosis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Experimental: H.P. Achtar Gel 80 U
Arm Type
Experimental
Arm Description
H.P. Acthar Gel (repository corticotropin) Injection, 80 U daily for 10 days, then 80 U twice weekly for up to a total of 48 weeks on therapy.
Intervention Type
Drug
Intervention Name(s)
Repository Corticotropin Injection
Other Intervention Name(s)
H.P. Acthar Gel, ACTH Gel, ACTH
Intervention Description
Initial treatment with 80 units daily for ten days (induction phase)
Maintenance treatment with 80 units twice weekly (maintenance phase)
Primary Outcome Measure Information:
Title
Proportion of patients with clinically significant improvement - successful glucocorticoid tapering.
Time Frame
12 Weeks
Secondary Outcome Measure Information:
Title
Proportion of patients with clinically significant improvement - no need for escalation of other therapy.
Time Frame
12 Weeks
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient with sarcoidosis as defined by ATS/ERS/WASOG (American Thoracic Society/European Thoracic Society/World Association for Sarcoidosis and Other Granulomatous Disorders)
Stable baseline immunosuppressive medications
Moderate to severe disease as defined by at least one of the following criteria:
Cranial nerve palsy
Neurologic deficits related to intraparenchymal brain, spinal cord and/or cauda equina involvement
Dural or leptomeningeal involvement of brain and/or spinal cord
Hydrocephalus
Seizures
Exclusion Criteria:
Diagnosis of any underlying neurologic disorder that would potentially confound interpretation of the study results
Significant change in corticosteroid dose within the past 4 weeks, or other immunosuppressive medication within the past 6 months
Evidence of current serious infection, or a history of chronic or recurring infections.
Contraindication to high-dose corticosteroids (e.g. uncontrolled blood sugar).
Allergies to pig-derived proteins
Have a history of any opportunistic infection within 6 months prior to screening
History of malignancy.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Daniel Culver, DO
Organizational Affiliation
The Cleveland Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cleveland Clinic Main Campus
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
ACTHAR Therapy for Central Nervous System Sarcoidosis
We'll reach out to this number within 24 hrs